Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors A Subgroup Analysis of the Phase III RADIANT-3 Trial

Catherine Lombard-Bohas,James C. Yao,Timothy James Hobday,Eric Van Cutsem,Edward M. Wolin,Ashok Panneerselvam,Sotirios G. Stergiopoulos,Manisha H. Shah,Jaume Capdevila,Rodney F. Pommier

Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors A Subgroup Analysis of the Phase III RADIANT-3 Trial

2015

Catherine Lombard-Bohas
James C. Yao
Timothy James Hobday
Eric Van Cutsem
Edward M. Wolin
Ashok Panneerselvam
Sotirios G. Stergiopoulos
Manisha H. Shah
Jaume Capdevila
Rodney F. Pommier

Objective The aim of this study was to evaluate efficacy and safety of everolimus in patients with pancreatic neuroendocrine tumors (pNET) by prior chemotherapy use in the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3).

Keywords:

Proportional hazards model
Endocrinology
Prospective cohort study
Internal medicine
Subgroup analysis
Diabetes mellitus
Neuroendocrine tumors
Everolimus
Chemotherapy
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations